Sinovac Biotech Ltd. is a biopharmaceutical company based in China that specializes in the development and manufacturing of vaccines for human infectious diseases. Its range of vaccines includes products to protect against enterovirus71, hepatitis A and B, seasonal influenza, and H5N1 and H1N1 pandemics. The company's EV71 vaccine, designed to combat hand, foot and mouth disease caused by EV71, was introduced to the Chinese market in 2016. Sinovac's Healive hepatitis A vaccine received prequalification approval by the WHO in 2017. In 2009, Sinovac was the first company globally to have its H1N1 influenza vaccine approved, which has been a part of China's vaccination program and stockpiling initiative.